Pfizer to Leverage Chai Discovery’s AI Platform

Editor’s Take: Chai’s agreement with Pfizer demonstrates the increasing speed of adoption of AI models by major pharmaceutical companies. Learn how AI is reshaping early drug development.

Pfizer has entered a license agreement with Chai Discovery, a company engineering AI models to discover new molecules.

The agreement will enable Pfizer to deploy Chai’s AI platform as part of its drug discovery engine, gaining early access to the Chai-3 model as well as a custom model that leverages Pfizer’s proprietary data and is tailored to Pfizer’s workflows.

Chai Discovery builds generative AI software that can predict and reprogram the interactions between molecules, enabling scientists to design biomolecules with specific functional properties. Chai’s frontier AI models can accelerate the early phases of development by designing new biomolecules from scratch, tackling hard targets, and compressing discovery loops from months or years into short sprints.

“Our work with Pfizer is about putting Chai’s software directly into the hands of one of the world’s leading drug discovery organizations,” said Joshua Meier, co-founder of Chai Discovery. “By combining Chai’s frontier AI platform with Pfizer’s scientific depth, data and discovery capabilities, we see an opportunity to expand and accelerate what is possible in biologics discovery and help Pfizer pursue targets that traditional methods have struggled to reach.”